Vedolizumab Plus Standard Prophylaxis Reduces Rate of Lower GI aGVHD
The addition of vedolizumab added to standard prophylaxis following unrelated allogeneic hematopoietic stem cell transplantation was superior to placebo at preventing lower gastrointestinal acute graft-vs-host disease.
Tisa-cel Reinfusion Shows Potential as HSCT Bridging Therapy in Pediatric B-ALL
February 19th 2023Second infusion with tisagenlecleucel after prior tisagenlecleucel infusion produced short durations of minimal residual disease-negative responses in children and young adults with B-cell acute lymphoblastic leukemia.
Ide-Cel Improves PFS and ORR in Triple-Class Exposed, Early R/R Multiple Myeloma
February 19th 2023Idecabtagene vicleucel demonstrated a statistically significant and clinically meaningful improvement in progression-free survival and objective response compared with standard of care approaches in patients with triple-class-exposed relapsed/refractory multiple myeloma.
Chronic Opioid Use Following ASCT Linked With Poor Survival Outcomes in Multiple Myeloma
February 18th 2023Patients with multiple myeloma who were treated with autologous stem cell transplantation were found to be utilizing chronic opioids at high rates, in turn leading to worse overall survival outcomes at 6 months of follow-up.
Dr. Nieto on High-Dose Chemotherapy and ASCT in R/R Multiple Myeloma
February 18th 2023Yago L. Nieto, MD, PhD, professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses findings from a phase 2 trial investigating panobinostat (Farydak), gemcitabine, busulfan, and melphalan plus autologous stem cell transplant (ASCT) in patients with high-risk or relapsed/refractory multiple myeloma.
Dr. Srour on Orca-Q Transplantation in Hematologic Malignancies
February 18th 2023Samer A. Srour, MB ChB, MS, discusses findings with Orca-Q, an investigational therapy consisting of enriched CD34+ stem cells plus T-cell subsets, in patients with high-risk hematologic malignancies eligible for myeloablative conditioning and allogeneic stem cell transplant.
Novel Therapies Are Needed to Reduce Cost Burden With AlloHCT, GVHD
Because of an economic burden on the healthcare system occurring through the per-patient cost of allogeneic hematopoietic cell transplant, novel treatments to replace transplant and prevent graft-vs-host disease are necessary.